Work

Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Year: 2016

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v128.22.1105.1105

Authors: Alex F Herrera, Nancy L Bartlett, Radhakrishnan Ramchandren, Julie M Vose, Alison J Moskowitz, Tatyana A Feldman, Ann S LaCasce, Stephen M Ansell, Craig H. Moskowitz, Keenan Fenton, Kazunobu Kato, Abraham Fong, Ranjana H Advani

Institutions: City Of Hope National Medical Center, Washington University in St. Louis, Alvin J. Siteman Cancer Center, The Barbara Ann Karmanos Cancer Institute, University of Nebraska Medical Center, Memorial Sloan Kettering Cancer Center, Hackensack University Medical Center, Dana-Farber Cancer Institute, Mayo Clinic, Seagen (United States), Bristol-Myers Squibb (United States), Stanford Medicine

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2765568148

FWCI: 5.751

Cites:

Cited by: 25

Related to: 10